PATHOLOGY – AUSTRALIA

‘Unsolicited offers’ for Healthscope arm

roymorgansocial Leave a comment

Original article by Tim Binsted
The Australian Financial Review – Page: 21 : 26-May-15

The pathology division of Healthscope boasts a market share of about 13 per cent, but its EBITDA for the first half of 2014-15 fell by 23 per cent to $A9.3m. Factors such as competition in the sector and a reduction in Medicare fees have also affected revenue. Healthscope CEO Robert Cooke says the group is often is approached about selling parts of its business but stresses that a sale process for the pathology unit is not underway.

CORPORATES
HEALTHSCOPE LIMITED – ASX HSO, SONIC HEALTHCARE LIMITED – ASX SHL, PRIMARY HEALTH CARE LIMITED – ASX PRY, CLSA AUSTRALIA PTY LTD, CRESCENT CAPITAL PARTNERS LIMITED, AUSTRALIA. DEPT OF HUMAN SERVICES. MEDICARE AUSTRALIA, AUSTRALIAN COMPETITION AND CONSUMER COMMISSION

Sonic hit by Medicare co-payment concerns

roymorgansocial Leave a comment

Original article by Jessica Gardner
The Australian Financial Review – Page: 19 : 18-Feb-15

Sonic Healthcare has posted a 2014-15 interim profit of $A174m, which is 1.9 per cent lower than previously. EBITDA of $A344m was in line with the previous corresponding period, but CEO Colin Goldschmidt anticipates full-year growth of 2-4 per cent. He notes that uncertainty about Medicare co-payments affected the group’s pathology business in the first half. Sonic shares closed 0.2 per cent lower at $A18.91 on 17 February 2015

CORPORATES
SONIC HEALTHCARE LIMITED – ASX SHL, INDEPENDENT PRACTITIONER NETWORK LIMITED, MEDIBANK PRIVATE LIMITED – ASX MPL, AUSTRALIA. DEPT OF HUMAN SERVICES. MEDICARE AUSTRALIA, AUSTRALIAN ETHICAL INVESTMENT LIMITED – ASX AEF